{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:57:25Z","timestamp":1782745045911,"version":"3.54.5"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Bispecific antibodies represent an important innovation in the field of biomedicine in recent years. Compared to monoclonal antibodies, their specific structure enables a single antibody molecule to bind to two different antigens simultaneously. This characteristic endows bispecific antibodies with more functions, regulating multiple signal pathways simultaneously, enhancing the therapeutic effect, and by infusion of targeted tumor antigens and drug carriers in advance, the contact time between the drug and normal tissues is reduced, and the toxic side effects are greatly reduced. They have shown promising application prospects, especially in dermatology and other fields. This article reviews the basic concepts of bispecific antibodies and their potential application in the treatment of skin diseases, including inflammatory skin diseases, skin tumors, and infectious skin diseases. The aim is to explore the current application status and future development directions of bispecific antibodies in dermatology, so as to provide references for related research and clinical practice.<\/jats:p>","DOI":"10.3389\/falgy.2025.1668931","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:14:30Z","timestamp":1755663270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances of bispecific antibodies using\/application in dermatology: a review"],"prefix":"10.3389","volume":"6","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Xiong","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2217\/1750743X.1.2.211","article-title":"Bispecific antibodies for cancer therapy","volume":"1","author":"Hollander","year":"2009","journal-title":"Immunotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.13345\/j.cjb.220911","article-title":"Single chain antibody fragment display systems: a review","volume":"39","author":"Chen","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"B3","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","article-title":"Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma","volume":"17","author":"Long","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis\u2013current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/nu12020411","article-title":"Inhibitory effect of Centella asiatica extract on DNCB-induced atopic dermatitis in HaCaT cells and BALB\/c mice","volume":"12","author":"Lee","year":"2020","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.3390\/ijms241612975","article-title":"Role of innate immunity in allergic contact dermatitis: an update","volume":"24","author":"Yamaguchi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2023.06.007","article-title":"Potential roles of inflammasomes in the pathophysiology of psoriasis: a comprehensive review","volume":"161","author":"Shahi","year":"2023","journal-title":"Mol Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.biopha.2018.09.178","article-title":"Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor \u03b1 on imiquimod-induced psoriasis in mice","volume":"108","author":"Liu","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis","volume":"17","author":"Dubin","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/pharmaceutics15020577","article-title":"Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis","volume":"15","author":"Orfali","year":"2023","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/ijms21041314","article-title":"The role of Th17-related cytokines in atopic dermatitis","volume":"21","author":"Sugaya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.mam.2021.100981","article-title":"The dual function of ILC2: from host protection to pathogenic players in type 2 asthma","volume":"80","author":"Maggi","year":"2021","journal-title":"Mol Aspects Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1517\/14728222.2014.965682","article-title":"Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach","volume":"19","author":"Di Lernia","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2280991","DOI":"10.1080\/07853890.2023.2280991","article-title":"Study of cytokine-induced immunity in bullous pemphigoid: recent developments","volume":"55","author":"Huang","year":"2023","journal-title":"Ann Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1039\/C8BM00843D","article-title":"Increased extracellular matrix density disrupts E-cadherin\/\u03b2-catenin complex in gastric cancer cells","volume":"6","author":"Jang","year":"2018","journal-title":"Biomater Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e7532","DOI":"10.1002\/ccr3.7532","article-title":"Psoriasis-like skin rash triggered by a local infection in a patient with eosinophilic granulomatosis with polyangiitis that was well controlled by mepolizumab treatment","volume":"11","author":"Yokota","year":"2023","journal-title":"Clin Case Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"A373","DOI":"10.1016\/j.jval.2014.08.2575","article-title":"Relative efficacy and safety of ustekinumab compared to anti-TNF-alfa therapies in patients with active psoriatic arthritis","volume":"17","author":"Huszti","year":"2014","journal-title":"Value Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/09546634.2017.1406894","article-title":"A systematic review of ustekinumab in the treatment of atopic dermatitis","volume":"29","author":"Pan","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41587-024-02221-3","article-title":"Antivenom slithers back to life","volume":"42","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"114135","DOI":"10.1016\/j.bcp.2020.114135","article-title":"Snake antivenom: challenges and alternate approaches","volume":"181","author":"Alangode","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/antibiotics13111046","article-title":"Potential therapeutic targets for combination antibody therapy against Staphylococcus aureus infections","volume":"13","author":"Ke","year":"2024","journal-title":"Antibiotics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1586\/14760584.2014.932253","article-title":"Candida antigens and immune responses: implications for a vaccine","volume":"13","author":"Moragues","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3324\/haematol.2023.283815","article-title":"Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia","volume":"109","author":"Brivio","year":"2024","journal-title":"Haematologica"},{"key":"B54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J Control Release"},{"key":"B55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/protein\/gzv034","article-title":"AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use\u2014improves psoriasis in a human xenograft transplantation model","volume":"28","author":"Stenderup","year":"2015","journal-title":"Protein Eng Des Sel"},{"key":"B56","doi-asserted-by":"publisher","first-page":"694","DOI":"10.36849\/JDD.8381","article-title":"Rapid remission of plaque psoriasis with bimekizumab treatment","volume":"23","author":"Abdin","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F Nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"MAbs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual Variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/rheumatology\/key312","article-title":"Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis","volume":"58","author":"Khatri","year":"2019","journal-title":"Rheumatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"112383","DOI":"10.1016\/j.intimp.2024.112383","article-title":"Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-\u03b1 and IL-17A, in autoimmune disease models","volume":"136","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B63","first-page":"890","article-title":"Inhibitory effect of bispecific antibody targeting IL-12 p40 and TNF-\u03b1 simultaneously on psoriasis in mice","volume":"33","author":"Xu","year":"2017","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B65","doi-asserted-by":"publisher","first-page":"eaaw2938","DOI":"10.1126\/sciimmunol.aaw2938","article-title":"A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis","volume":"5","author":"Bitton","year":"2020","journal-title":"Sci Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2020.05.003","article-title":"Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial","volume":"84","author":"Merola","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/ijms24010372","article-title":"IL-33 and IL-37: a possible axis in skin and allergic diseases","volume":"24","author":"Borgia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1442588","DOI":"10.3389\/fimmu.2024.1442588","article-title":"A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases","volume":"15","author":"Shi","year":"2024","journal-title":"Front Immunol"},{"key":"B75","first-page":"21","article-title":"Role of production of type I interferons by B cells in the mechanisms and pathogenesis of systemic lupus erythematosus","volume":"25","author":"Hamilton","year":"2018","journal-title":"Discov Med"},{"key":"B76","first-page":"2867","article-title":"Changes of serum IL-6, IL-10 and TNF-\u03b1 levels in patients with systemic lupus erythematosus and their clinical value","volume":"13","author":"Jin","year":"2021","journal-title":"Am J Transl Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"970906","DOI":"10.3389\/fimmu.2022.970906","article-title":"IL-10 revisited in systemic lupus erythematosus","volume":"13","author":"Biswas","year":"2022","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/1744666X.2019.1593141","article-title":"The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target","volume":"15","author":"Koga","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"991","DOI":"10.4161\/mabs.28841","article-title":"Suppression of innate and adaptive B cell activation pathways by antibody coengagement of Fc\u03b3RIIb and CD19","volume":"6","author":"Szili","year":"2014","journal-title":"MAbs"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"B83","first-page":"906","article-title":"Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment","volume":"37","author":"Zhang","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cpt.2929","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic properties of rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase I clinical trials","volume":"114","author":"Abuqayyas","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/acr2.11487","article-title":"Safety and biological activity of rozibafusp alfa, a bispecific inhibitor of inducible costimulator ligand and B cell activating factor, in patients with rheumatoid arthritis: results of a phase 1b, randomized, double-blind, placebo-controlled, multiple ascending dose study","volume":"4","author":"Abuqayyas","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e000890","DOI":"10.1136\/lupus-2022-000890","article-title":"Improving resource utilisation in SLE drug development through innovative trial design","volume":"10","author":"Garces","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2014at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/jcm11051310","article-title":"Future treatment options in systemic sclerosis\u2014potential targets and ongoing clinical trials","volume":"11","author":"Bohdziewicz","year":"2022","journal-title":"J Clin Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"999008","DOI":"10.3389\/fimmu.2022.999008","article-title":"Dysregulated B cell function and disease pathogenesis in systemic sclerosis","volume":"13","author":"Beesley","year":"2023","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1022228","DOI":"10.3389\/fimmu.2022.1022228","article-title":"The role of PD-1\/PD-L1 axis in idiopathic pulmonary fibrosis: friend or foe?","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.medcli.2022.10.007","article-title":"S\u00edndrome de sj\u00f6gren","volume":"160","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"Med Clin"},{"key":"B94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol Biomed"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e006436","DOI":"10.1136\/jitc-2022-006436","article-title":"Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma","volume":"11","author":"M\u00e4rkl","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"837889","DOI":"10.3389\/fphar.2022.837889","article-title":"Bispecific antibodies progression in malignant melanoma","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.matbio.2018.03.016","article-title":"Biomechanical and biomolecular characterization of extracellular matrix structures in human colon carcinomas","author":"Brauchle","year":"2018","journal-title":"Matrix Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","article-title":"T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities","volume":"34","author":"Baeuerle","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"B103","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0300985815604724","article-title":"CD3 and CD20 coexpression in a case of canine cutaneous epitheliotropic T-cell lymphoma (mycosis fungoides)","volume":"53","author":"Brachelente","year":"2016","journal-title":"Vet Pathol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"key":"B105","doi-asserted-by":"publisher","first-page":"102042","DOI":"10.1016\/j.ctrv.2020.102042","article-title":"Immunotherapy in Hodgkin and non-Hodgkin lymphoma: innate, adaptive and targeted immunological strategies","volume":"88","author":"Tun","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B106","doi-asserted-by":"publisher","first-page":"16404","DOI":"10.1073\/pnas.1102265108","article-title":"Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins","volume":"108","author":"Laventie","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e00629-17","DOI":"10.1128\/AAC.00629-17","article-title":"Multimechanistic monoclonal antibodies (MAbs) targeting Staphylococcus aureus alpha-toxin and clumping factor A: activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach","volume":"61","author":"Tkaczyk","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0148714","DOI":"10.1371\/journal.pone.0148714","article-title":"A murine, bispecific monoclonal antibody simultaneously recognizing \u03b2-glucan and MP65 determinants in Candida Species","volume":"11","author":"Zito","year":"2016","journal-title":"PLoS One"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e002454","DOI":"10.1136\/jitc-2021-002454","article-title":"Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy","volume":"9","author":"Ravirala","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"key":"B112","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B113","doi-asserted-by":"publisher","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"107160","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"B118","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1668931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:14:33Z","timestamp":1755663273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1668931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":119,"alternative-id":["10.3389\/falgy.2025.1668931"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1668931","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1668931"}}